A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer

The Multicenter, Phase II Prospective Study of Paclitaxel Plus Capecitabine as First-Line Chemotherapy in Advanced Gastric Carcinoma

(2014) J. Gong et al.   ONCOLOGIST

Paclitaxel combined with capecitabine as first-line chemotherapy for advanced or recurrent gastric cancer

(2014) MEIQIN YUAN et al.   Oncology Letters

Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2013) T. Waddell et al.   ANNALS OF ONCOLOGY

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

(2009) Y.-K. Kang et al.   ANNALS OF ONCOLOGY

ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer

(2009) Min-Hee Ryu et al.   Expert Review of Anticancer Therapy

Paclitaxel chemotherapy for the treatment of gastric cancer

(2009) Junichi Sakamoto et al.   Gastric Cancer

A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer

(2008) H J Kang et al.   BRITISH JOURNAL OF CANCER